Brief: Aptevo Therapeutics Announces Launch Of Its Second Platform Technology, Introduces New Bispecific Prostate Cancer Candidate
02/12/2020 13:23
Dec 2 (Reuters) - Aptevo Therapeutics Inc APVO.O :
* APTEVO THERAPEUTICS - ANNOUNCES LAUNCH OF ITS SECOND
PLATFORM
TECHNOLOGY ADAPTIR-FLEX AND INTRODUCES NEW BISPECIFIC PROSTATE
CANCER CANDIDATE APVO442
* APTEVO THERAPEUTICS INC - APVO442 IS A UNIQUE T-CELL
ENGAGER
DESIGNED TO TARGET PSMA AND CD3 FOR TREATMENT OF PROSTATE CANCER
Source text for Eikon: [ID:https://bit.ly/3mraQhz]
Further company coverage: APVO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aptevo Therapeutics
See all newsBrief: Aptevo Therapeutics - Enters Amendment No. 6 To Rights Agreement On October 23, 2026 - SEC Filing
U.S. STOCKS ON THE MOVE-Principal Financial Group, NetApp
U.S. STOCKS ON THE MOVE-Genesco, Fervo Energy, Tyson Foods
Aptevo Therapeutics reports early data for blood cancer therapy; shares fall
Aptevo Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary